Yissum - Research Development Company of the Hebrew University

Oral Delivery Platform for Lipophilic Drugs Based on Pro-Nano Lipospheres

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Cluster9
Dispersible Concentrate Lipospheres for the Delivery of Agents (PNL)
Project ID : 6-2017-4492

Yissum - Research Development Company of the Hebrew University

Description of the technology

Categories:

Life Science & Biotechnology

Technology Keywords:

Formulation, drug delivery, increased bioavailability

Development Stage:

POC in Human

Highlights

The P-gp efflux and oxidative Phase I metabolism are major predicaments in drug absorption and oral delivery of small molecules. The Pro-Nano Lipospheresvehicle serves as a platform for the successful oral delivery of lipophilic drugs. The proposed formulation improves the oral administration of clinically relevant molecules, which are otherwise prone to low oral bioavailability.

Our Innovation

  • The PNL formulation is composed of GRAS status[1] materials
  • Enables oral administration of drugs, which is a key component in patient compliance compared to other routes.
  • Overcomes absorption obstacles of lipophilic drugs: improved solubility in the GI tract and decreased intestinal first pass metabolism
  • The ratio between components can be adjusted so that an optimal nano emulsion is formed with a plethora of compounds.

Technology

The poorly absorbed drug is dissolved in the oily formulation. Upon contact with water, the formulation forms nano particles. Theses nano particles trap the lipophilic components in their lipid core. Thus, the lipophilic drug is solubilized in the aqueous environment of the GI. When reaching the intestine monolayer, the formulation’s excipients (surfactants and medium chain triglyceride) diminishes the drug’s metabolism and efflux from the enterocytes.

  • The formulation self emulsifies in the GI milieu forming an O/W nano emulsion with particle size of 50nm and less (Figure 1)

Figure 1: Clear o/w nano-emulsion formation upon PNL dilution with water

Opportunity

Many of today’s leading compounds and drugs in pipeline fail to reach clinical stages due to poor oral bioavailability. This formulation presents an ideal, simple solution for the optimal oral delivery of these compounds and a direct to clinic development.

Increase in oral bioavailability leads a lower inter and intra subject variability

[1] GRAS - Generally Recognized As Safe

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Amnon Hoffman
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Abraham Domb
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • Drug delivery

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.